Lufax Receives NYSE Notice Regarding Late Filing of Annual Report on Form 20-F
The Company will have until October 30, 2025 to file the annual report with the SEC and regain compliance with the NYSE's continued listing standards. If the Company fails to file the annual report by October 30, 2025, the NYSE may grant the Company an extension until April 30, 2026. If the NYSE does not grant an extension after the Company fails to file the annual report by October 30, 2025, suspension and delisting procedures will commence pursuant to the procedures set out in Section 804.00 of the Listed Company Manual. If the NYSE grants an extension but the Company fails to file the annual report by the end of the extension period, suspension and delisting procedures will also commence. The Company intends to regain compliance with the NYSE's continued listing standards by filing the annual report within the NYSE's prescribed timelines.
The notice from the NYSE has no immediate impact on the listing of the Company's American depositary shares on the NYSE.
The Company was unable to file the annual report by the prescribed due date due to the proposed change in the Company's auditors. The board of directors of the Company has resolved to appoint Ernst & Young and Ernst & Young Hua Ming LLP as the new auditors of the Company, subject to the passing of an ordinary resolution at an extraordinary general meeting currently scheduled for June 25, 2025. The Company expects to file its 2024 annual report promptly after the new auditors have completed their audit of the financial statements required to be included therein.
About Lufax
Lufax is a leading financial services enabler for small business owners in China. Lufax offers financing products designed to address the needs of small business owners and others. In doing so, Lufax has established relationships with 85 financial institutions in China as funding partners, many of which have worked with Lufax for over three years.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about Lufax's beliefs and expectations, are forward-looking statements. Lufax has based these forward-looking statements largely on its current expectations and projections about future events and financial trends, which involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. These forward-looking statements include, but are not limited to, statements about Lufax's goals and strategies; Lufax's future business development, financial condition and results of operations; expected changes in Lufax's income, expenses or expenditures; expected growth of the retail credit enablement; Lufax's expectations regarding demand for, and market acceptance of, its services; Lufax's expectations regarding its relationship with borrowers, platform investors, funding sources, product providers and other business partners; general economic and business conditions; and government policies and regulations relating to the industry Lufax operates in. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Lufax's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Lufax does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact
Lufax Holding LtdEmail: Investor_Relations@lu.com
ICR, LLCRobin YangTel: +1 (646) 308-0546Email: lufax.ir@icrinc.com
View original content:https://www.prnewswire.com/news-releases/lufax-receives-nyse-notice-regarding-late-filing-of-annual-report-on-form-20-f-302453930.html
SOURCE Lufax Holding Ltd
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Humana (HUM) To Report Earnings Tomorrow: Here Is What To Expect
Health insurance company Humana (NYSE:HUM) will be announcing earnings results this Wednesday morning. Here's what you need to know. Humana met analysts' revenue expectations last quarter, reporting revenues of $32.11 billion, up 8.4% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates but a significant miss of analysts' customer base estimates. It lost -1.51 million customers and ended up with a total of 14.84 million. Is Humana a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Humana's revenue to grow 7.8% year on year to $31.86 billion, slowing from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.87 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Humana has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 2% on average. Looking at Humana's peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Centene delivered year-on-year revenue growth of 22.4%, beating analysts' expectations by 11.6%, and Molina Healthcare reported revenues up 15.7%, topping estimates by 4.4%. Centene's stock price was unchanged after the resultswhile Molina Healthcare was down 16.9%. Read our full analysis of Centene's results here and Molina Healthcare's results here. Investors in the health insurance providers segment have had steady hands going into earnings, with share prices flat over the last month. Humana is down 4.9% during the same time and is heading into earnings with an average analyst price target of $285.36 (compared to the current share price of $232.40). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Timken (TKR) Reports Earnings Tomorrow: What To Expect
Industrial component provider Timken (NYSE:TKR) will be announcing earnings results this Wednesday before market open. Here's what investors should know. Timken beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $1.14 billion, down 4.2% year on year. It was a slower quarter for the company, with a significant miss of analysts' adjusted operating income estimates and full-year EPS guidance missing analysts' expectations. Is Timken a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Timken's revenue to decline 3% year on year to $1.15 billion, improving from the 7.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.36 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 3 downward revisions over the last 30 days (we track 8 analysts). Timken has missed Wall Street's revenue estimates twice over the last two years. Looking at Timken's peers in the industrial machinery segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Worthington posted flat year-on-year revenue, beating analysts' expectations by 5.6%, and GE Aerospace reported revenues up 21.2%, topping estimates by 15.6%. Worthington traded up 1.8% following the results while GE Aerospace was down 1.1%. Read our full analysis of Worthington's results here and GE Aerospace's results here. There has been positive sentiment among investors in the industrial machinery segment, with share prices up 6.5% on average over the last month. Timken is up 12.6% during the same time and is heading into earnings with an average analyst price target of $82.90 (compared to the current share price of $81.69). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
Altria (MO) Reports Q2: Everything You Need To Know Ahead Of Earnings
Tobacco company Altria (NYSE:MO) will be reporting results this Wednesday before market hours. Here's what investors should know. Altria missed analysts' revenue expectations by 2.5% last quarter, reporting revenues of $4.52 billion, down 4.2% year on year. It was a mixed quarter for the company, with a decent beat of analysts' EBITDA estimates but a significant miss of analysts' gross margin estimates. Is Altria a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Altria's revenue to decline 1.5% year on year to $5.20 billion, improving from the 3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.38 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Altria has missed Wall Street's revenue estimates six times over the last two years. Looking at Altria's peers in the beverages, alcohol, and tobacco segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Beer delivered year-on-year revenue growth of 1.5%, meeting analysts' expectations, and Coca-Cola reported revenues up 2.1%, topping estimates by 0.5%. Boston Beer traded up 6.5% following the results while Coca-Cola was down 1.4%. Read our full analysis of Boston Beer's results here and Coca-Cola's results here. There has been positive sentiment among investors in the beverages, alcohol, and tobacco segment, with share prices up 3.8% on average over the last month. Altria's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $58.54 (compared to the current share price of $58.94). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
